Cerevel Therapeutics Holdings Inc. is set to be delisted from NASDAQ following its acquisition by AbbVie, which is scheduled to close prior to market open on August 1, 2024. The stock will be halted immediately after the after-hours session on July 31, 2024, around 7:50 PM. Following the acquisition, Cerevel shares have generated a total return of 288%, reflecting a compound annual growth rate (CAGR) of 40.3%. This acquisition marks a significant milestone for Cerevel, recognized as one of the most successful deSPACs to date. The transaction was facilitated by the ARYA Sciences SPAC team, who were instrumental in taking Cerevel public.